Novel treatment approaches of SLE have recently been reviewed, and while Belimumab is approved, Atacicept, a combined BAFF/APRIL inhibitor [55], is being further studied in phase II/III clinical trials [56]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.